Description: IsoRay, Inc. engages in the development, manufacture, and sale of isotope-based medical products and devices for the treatment of cancer and other malignant diseases primarily in the United States. The company produces Proxcelan Cesium-131 brachytherapy seeds that are used for the treatment of prostate cancer; ocular melanoma; head, neck, and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer; and pancreatic cancers. It also offers GliaSite radiation therapy system, a balloon catheter device, which is used to treat brain cancer. IsoRay, Inc. is based in Richland, Washington.
Home Page: isoray.com
ISR Technical Analysis
350 Hills Street
Richland,
WA
99354
United States
Phone:
509 375 1202
Officers
| Name | Title |
|---|---|
| Ms. Lori A. Holmes-Woods | CEO & Director |
| Ms. Jennifer Streeter | COO & VP of HR |
| Mr. William A. Cavanagh III | Chief R&D Officer |
| Mr. Jonathan R. Hunt | CFO & Co-Principal Financial Officer |
| Mr. Mark J. Austin CPA | VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec. |
| Ms. Krista Cline | Sr. Director of Operations & Corp. Sec. |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7389 |
| Price-to-Sales TTM: | 4.1428 |
| IPO Date: | 2005-11-10 |
| Fiscal Year End: | June |
| Full Time Employees: | 66 |